The study examined the association between current hormonal contraception and the risk of leukemia in 1,957,490 premenopausal women aged 15–49 years in Denmark from 1995–2021, followed for 24.5 million person-years. 671 cases of leukemia were recorded. The incidence of leukemia in current and recent users was similar to women who had never used hormonal contraception: adjusted incidence rate ratio (IRR) 0.95 (95% CI 0.78–1.16; p=0.62). No association was found with different durations of use (0–5 years: IRR 0.93; >5–10 years: IRR 1.16; >10 years: IRR 0.67) or time since last use (0–5 years: IRR 1.01; >5–10 years: IRR 1.05; >10 years: IRR 0.88). Similar results were valid for different types of contraception, such as combined products (IRR 0.91) or progestin-only (IRR 1.05), and for specific types of leukemia. Current hormonal contraception was not associated with the risk of leukemia regardless of product, duration of use, time since last use, or type of leukemia. The main limitation was the small number of cases in some analyses.